← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #486 OF 1,000 MOST-CITED

Control of treated animals

FDA cited this observation 49 times across 48 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Veterinary Medicine49
BY FISCAL YEAR
FY20252
FY20242
FY20232
FY20222
FY20203
FY20193
FY201810
FY201711
FY201614

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 2.7× the rate of the average FDA-cited firm (20.8% vs 7.7%), across 48 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

You did not identify and segregate treated animals.

Ogle Cattle Company, Inc. · Bowie, Texas · Veterinary Medicine · 2025-05-06

You did not identify treated animals.

J.A. Timmerman Cattle Company · La Salle, Colorado · Veterinary Medicine · 2025-03-27

You did not identify treated animals.

Steinhorst Farms · Kewaunee, Wisconsin · Veterinary Medicine · 2023-12-14

You did not identify and segregate treated animals.

Gary Horst · Lebanon, Pennsylvania · Veterinary Medicine · 2023-10-20

You did not identify and segregate treated animals.

Larry Fryfogle · Beloit, Ohio · Veterinary Medicine · 2023-06-07

You did not identify and segregate treated animals.

Dayna Candler · Clear Lake, Wisconsin · Veterinary Medicine · 2023-06-05

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Veterinary industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →